Cogent Biosciences (COGT) News Today $7.84 +0.04 (+0.51%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period State Street Corp Sells 605,500 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)State Street Corp cut its holdings in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 15.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,231,462 shares of the technology companyDecember 21 at 3:40 AM | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by AnalystsShares of Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven brokerages that are presently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and four hDecember 20 at 5:09 AM | marketbeat.comCogent Biosciences (NASDAQ:COGT) Stock Price Down 4.4% - What's Next?Cogent Biosciences (NASDAQ:COGT) Stock Price Down 4.4% - Time to Sell?December 18 at 5:12 PM | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Sees Large Increase in Short InterestCogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) was the target of a significant growth in short interest in the month of November. As of November 30th, there was short interest totalling 8,420,000 shares, a growth of 9.1% from the November 15th total of 7,720,000 shares. Based on an average daily volume of 1,250,000 shares, the short-interest ratio is currently 6.7 days.December 16, 2024 | marketbeat.comHC Wainwright Has Negative Forecast for COGT FY2024 EarningsDecember 15, 2024 | americanbankingnews.comCogent Biosciences (NASDAQ:COGT) Downgraded by Needham & Company LLC to HoldDecember 14, 2024 | americanbankingnews.comHC Wainwright Has Negative Estimate for COGT FY2024 EarningsCogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Investment analysts at HC Wainwright lowered their FY2024 earnings estimates for shares of Cogent Biosciences in a research report issued on Wednesday, December 11th. HC Wainwright analyst R. Burns now anticipates that the technology companyDecember 13, 2024 | marketbeat.comNeedham Downgrades Cogent Biosciences (COGT)December 12, 2024 | msn.comHC Wainwright Reiterates Buy Rating for Cogent Biosciences (NASDAQ:COGT)HC Wainwright restated a "buy" rating on shares of Cogent Biosciences in a report on Wednesday.December 11, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Stock Rating Lowered by Needham & Company LLCNeedham & Company LLC lowered shares of Cogent Biosciences from a "buy" rating to a "hold" rating in a report on Wednesday.December 11, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Has $8.92 Million Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT)Charles Schwab Investment Management Inc. lifted its holdings in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 20.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 825,793 shares of the tDecember 11, 2024 | marketbeat.comNeedham & Company LLC Reiterates "Buy" Rating for Cogent Biosciences (NASDAQ:COGT)December 11, 2024 | americanbankingnews.comPromising Market Potential for Cogent Biosciences: A Buy Rating Backed by Efficacy and Safety of BezuclasinibDecember 10, 2024 | markets.businessinsider.comCogent Biosciences (NASDAQ:COGT) Earns "Buy" Rating from Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $15.00 target price on shares of Cogent Biosciences in a research report on Monday.December 9, 2024 | marketbeat.comCogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis PatientsDecember 9, 2024 | globenewswire.comCogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)December 8, 2024 | globenewswire.comFmr LLC Has $89.85 Million Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT)Fmr LLC increased its holdings in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 8.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,319,411 shares of the technology company's stock after purchasing an addDecember 6, 2024 | marketbeat.comRedmile Group LLC Sells 315,593 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)Redmile Group LLC decreased its position in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 6.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 4,484,380 shares of the technology company's stock after selling 315,593 shares during theDecember 5, 2024 | marketbeat.comBank of Montreal Can Invests $3.14 Million in Cogent Biosciences, Inc. (NASDAQ:COGT)Bank of Montreal Can purchased a new position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 287,610 shares of the technology companyDecember 5, 2024 | marketbeat.comWhy Is Cogent Biosciences, Inc. (COGT) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?December 4, 2024 | msn.comHighVista Strategies LLC Has $2.44 Million Stock Position in Cogent Biosciences, Inc. (NASDAQ:COGT)HighVista Strategies LLC cut its holdings in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 19.7% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 225,633 shares of the technology company's stock after selling 5December 3, 2024 | marketbeat.comCinctive Capital Management LP Buys 157,969 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)Cinctive Capital Management LP increased its stake in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 91.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 330,419 sharesDecember 3, 2024 | marketbeat.comWalleye Capital LLC Makes New Investment in Cogent Biosciences, Inc. (NASDAQ:COGT)Walleye Capital LLC bought a new stake in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 557,326 shares of the technology company's stock, valued atDecember 1, 2024 | marketbeat.comEventide Asset Management LLC Sells 479,357 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)Eventide Asset Management LLC trimmed its holdings in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 34.3% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 919,635 shares of the technology company's stock aftNovember 30, 2024 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Recommendation of "Moderate Buy" from AnalystsCogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven research firms that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and fiveNovember 25, 2024 | marketbeat.comFY2024 EPS Forecast for Cogent Biosciences Lifted by AnalystCogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Research analysts at Leerink Partnrs increased their FY2024 earnings per share estimates for shares of Cogent Biosciences in a note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst A. Berens now expects that the technoNovember 18, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Trading Down 7% - Should You Sell?Cogent Biosciences (NASDAQ:COGT) Trading Down 7% - Time to Sell?November 15, 2024 | marketbeat.comEquities Analysts Set Expectations for COGT FY2027 EarningsCogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Stock analysts at Leerink Partnrs raised their FY2027 earnings per share (EPS) estimates for Cogent Biosciences in a report released on Wednesday, November 13th. Leerink Partnrs analyst A. Berens now expects that the technology company will eNovember 15, 2024 | marketbeat.comWhat is Lifesci Capital's Estimate for COGT FY2024 Earnings?Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Research analysts at Lifesci Capital cut their FY2024 EPS estimates for shares of Cogent Biosciences in a note issued to investors on Wednesday, November 13th. Lifesci Capital analyst S. Slutsky now anticipates that the technology company wilNovember 15, 2024 | marketbeat.comWedbush Reduces Earnings Estimates for Cogent BiosciencesCogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Analysts at Wedbush decreased their FY2024 earnings per share (EPS) estimates for shares of Cogent Biosciences in a research report issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now forecasts that the technology company wiNovember 15, 2024 | marketbeat.comCogent Biosciences: Promising Clinical Developments and Strategic Milestones Warrant a Buy RecommendationNovember 14, 2024 | markets.businessinsider.comCogent Biosciences (NASDAQ:COGT) Issues Earnings ResultsCogent Biosciences (NASDAQ:COGT - Get Free Report) issued its quarterly earnings results on Tuesday. The technology company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.07). During the same period in the prior year, the firm earned ($0.64) EPS.November 13, 2024 | marketbeat.comNeedham & Company LLC Cuts Cogent Biosciences (NASDAQ:COGT) Price Target to $15.00Needham & Company LLC lowered their target price on Cogent Biosciences from $16.00 to $15.00 and set a "buy" rating for the company in a research note on Wednesday.November 13, 2024 | marketbeat.comCogent Biosciences Reports Progress in Clinical Trials and Financial StandingNovember 13, 2024 | markets.businessinsider.comBuy Recommendation for Cogent Biosciences Amid Unjustified Stock DeclineNovember 6, 2024 | markets.businessinsider.comCogent Biosciences (NASDAQ:COGT) Shares Down 5.3% - What's Next?Cogent Biosciences (NASDAQ:COGT) Trading Down 5.3% - Time to Sell?November 5, 2024 | marketbeat.comCogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) MeetingNovember 5, 2024 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for Cogent Biosciences (NASDAQ:COGT)HC Wainwright restated a "buy" rating and set a $17.00 target price on shares of Cogent Biosciences in a report on Monday.November 4, 2024 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Recommendation of "Moderate Buy" from BrokeragesCogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and five have issued a buyOctober 31, 2024 | marketbeat.comHennion & Walsh Asset Management Inc. Increases Stock Position in Cogent Biosciences, Inc. (NASDAQ:COGT)Hennion & Walsh Asset Management Inc. grew its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 34.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 171,9October 26, 2024 | marketbeat.comCogent Biosciences: Promising Pipeline and Strategic Positioning Drive Buy RatingOctober 25, 2024 | markets.businessinsider.comNeedham & Company LLC Reiterates Buy Rating for Cogent Biosciences (NASDAQ:COGT)Needham & Company LLC reissued a "buy" rating and issued a $16.00 target price on shares of Cogent Biosciences in a research report on Thursday.October 24, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Sets New 52-Week High - Here's What HappenedCogent Biosciences (NASDAQ:COGT) Hits New 52-Week High - What's Next?October 22, 2024 | marketbeat.comHere's Why We're Not Too Worried About Cogent Biosciences' (NASDAQ:COGT) Cash Burn SituationOctober 21, 2024 | finance.yahoo.comCogent Biosciences (NASDAQ:COGT) Trading Down 2.4% - Here's WhyCogent Biosciences (NASDAQ:COGT) Trading Down 2.4% - Should You Sell?October 16, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Shares Up 4.6% - Time to Buy?Cogent Biosciences (NASDAQ:COGT) Trading Up 4.6% - Still a Buy?October 10, 2024 | marketbeat.comAnalysts Rate Cogent Biosciences, Inc. (COGT) as Moderate Buy with $15 TargetOctober 10, 2024 | msn.comDimensional Fund Advisors LP Sells 463,901 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)Dimensional Fund Advisors LP trimmed its position in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 33.3% in the second quarter, according to its most recent filing with the SEC. The fund owned 930,297 shares of the technology company's stock after selling 463,901 shares during the period.October 8, 2024 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seven brokerages that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and five have given aOctober 6, 2024 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.com Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Email Address 70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today! (Ad)Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << COGT Media Mentions By Week COGT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COGT News Sentiment▼-0.080.60▲Average Medical News Sentiment COGT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COGT Articles This Week▼63▲COGT Articles Average Week Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PTC Therapeutics News Verona Pharma News Rhythm Pharmaceuticals News MoonLake Immunotherapeutics News Edgewise Therapeutics News Janux Therapeutics News Xenon Pharmaceuticals News Merus News ACADIA Pharmaceuticals News Twist Bioscience News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COGT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
